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THE EXTRAVASATION OF CYTOTOXIC CHEMOTHERAPY: A 
SYSTEMATIC REVIEW OF THE LITERATURE TO ESTABLISH THE 
LEVEL OF EVIDENCE UNDERPINNING CONTEMPORARY PRACTICE 
AND REVEAL ANY STUDIES THAT EXPLORE THE PATIENT 
EXPERIENCE, OR EVALUATE OUTCOME FROM THE PATIENT’S 
PERSPECTIVE.  
 
Background 
Extravasation is defined as the inadvertent administration of cytotoxic chemotherapy 
drugs with the ability to cause severe tissue damage, tissue necrosis, blistering or 
sloughing, into the surrounding tissues rather than into the vascular pathway as intended 
(Allwood et al 2002, Dougherty and Lister 2008, RCN 2010). 
 
Statistically the incidence of extravasation is low; with it estimated that 0.01% - 6.5% 
of all cytotoxic drug administrations’ will result in an extravasation (Albanell and 
Baselga 2000, Schulmeister 2011). However Wengstrom (2008) suggests that when 
judged against the number of adverse events associated with chemotherapy, such as 
neutropenic sepsis, mucositis and gastrointestinal disturbances, the absolute number of 
extravasations becomes significant. The outcome of an ineffectively managed 
extravasation can be potentially devastating (Ener et al 2004, Arroyo et al 2010, Roe 
2011, Schulmeister 2011) with long term consequences having the potential to be even 
more disabling for the patient than their primary disease (Gault 1993).  
 
Whilst there is a clear consensus of opinion that the regular training and education of all 
staff involved in the administration of cytotoxic chemotherapy, supported by up to date 
institutional policies and procedures, is a key factor in the effective prevention of 
extravasation (EONS 2007, UKONS 2008, Dougherty 2010, Schulmeister 2011);  it is 
also recognised that regardless of healthcare providers taking every precaution to 
prevent extravasation, and irrespective of the experience, skill and knowledge of the 
practitioner administering the cytotoxic chemotherapy, it will still occur (Dougherty 
2010, Schulmeister 2011).  
 
Despite this, opinion as to the most clinically effective management strategy remains 
contentious (Roe et al 2013). It is recognised that currently policies and procedures are 
largely empirical, based on historical practice within institutions, prior experience and 
observational data, on ‘expert’ opinion and from uncontrolled non randomised trials 
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(Mader et al 2011).   As such there is variation in practice, with some clinicians 
favouring the use of antidotes (Schulmeister 2011, Perez Fidalgo et al 2012) and others 
favouring use of saline washout (Steiert et al 2011, Harrold et al 2013).   
 
The Department of Health (DOH) is strongly committed to ensuring patients not only 
receive high quality care within an equitable service, but that the patient experience of 
the care provided also plays a significant part in the development  of clinical practice 
guidelines. By making clinical practice more ‘patient centred’ taking into account their 
opinion of the care provided, this aims to improve quality, outcome and experience 
(DOH 2010b, 2011b, 2011c, 2012a) with Doyle et al (2013) establishing that in many 
circumstances, clinical effectiveness and outcome are directly linked to patient 
experience. 
 
Objectives  
To establish the level of evidence that underpins contemporary practice in the 
management of cytotoxic chemotherapy extravasation, the number of studies supporting 
each management strategy and to investigate the prevalence of studies exploring the 
patient experience or evaluating outcome from the patient’s perspective.  
 
Research questions 
The questions this literature review addresses are: 
  What level of evidence supports the use of antidotes in the management of 
cytotoxic chemotherapy drug extravasation?  What level of evidence supports the use of saline wash out in the management 
cytotoxic chemotherapy drug extravasation?  Is there any evidence to clearly show one technique as being more effective than 
the other?  Are there any studies published that consider outcome from the patient’s 
perspective?  Are there any studies that explore the patient experience? 
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Method 
Search process 
A search of the literature was undertaken to source publications relating to 
extravasation management dating from the introduction of cytotoxic drugs as a cancer 
treatment in the 1960’s to December 1st 2012. This was undertaken by accessing Pub-
Med, Embase, Cinahl, Scopus, the British Nursing Index (BNI) and the Cochrane 
library for published clinical articles in professional and academic journals, including 
literature reviews, case studies and clinical trials, professional speciality text books, 
National and International Guidelines and pharmaceutical company literature. The 
United Kingdom national extravasation website was accessed; also a manual search of 
the bibliographies of associated articles and associated reference lists of the literature 
was carried out once sourced citations had been screened for eligibility. Details of the 
electronic search process can be found in Table 1.  
 
Screening process 
The identified literature was screened in accordance with the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis) four phase flow diagram 
(Moher et al 2009) and is presented in Table 2. 
 
Inclusion criteria 
Publications detailing non surgical management strategies in both the clinical and 
laboratory setting, which aimed to prevent ulceration or tissue necrosis following 
cytotoxic drug extravasation into the subcutaneous tissue of humans or animals. Both 
quantitative and qualitative studies were included with the purpose of identifying any 
studies which evaluated extravasation management from the patient’s perspective. 
Language restrictions: Only papers written or translated into English. 
 
Exclusion criteria 
All citations detailing surgical intervention, the treatment of ulceration as a result of 
ineffective extravasation management, or relating to the prevention of skin ulceration 
following the topical application of cytotoxic drugs were excluded.  
 
Also excluded were citations relating to the extravasation of contrast agents, analgesics, 
antibiotics, non chemotherapy vesicant drugs, liposomal cytotoxic drug preparations, 
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parenteral nutrition, anti-inflammatories, blood products or proteins and those relating 
to extravasation recall phenomenon, systemic toxicity from cytotoxic drug 
administration and records of dermatological toxicity from systemic therapies. 
 
All citations relating to chemotherapy extravasation into the mediastinum or 
intrapleural extravasation were excluded, plus papers reviewing the incidence of 
extravasations or detailing its potential causes, extravasation prevention protocols or 
risk management strategies, extravasation detection criteria, reporting criteria and those 
discussing the physiology of tissue necrosis following drug extravasation.  
 
Abstract review 
Full texts were retrieved from the sourced citations if the abstract fulfilled the inclusion 
criteria and addressed one or more of the research questions. Full text papers were also 
retrieved if no abstract was available, but the title indicated that it fulfilled one or more 
of the above criteria.   
 
Quality assessment and data extraction 
Publications were appraised and graded using tools based on The Oxford Centre for 
Evidence Based Medicine’s hierarchy of evidence levels (OCEBM 2011). 
 
Final screening process and analysis 
A Final analysis of the literature found there to be a significant lack of OCEBM level 1 
systematic reviews. This outcome is supported by the findings of Gopalakrishnan et al 
(2012) who could find only case reports and case series describing successful outcomes 
with different interventions when attempting to undertake a Cochrane Review on the 
management of skin extravasation injury in neonates. 
 
Similarly Drake (2012) carried out a short cut review to evaluate the evidence behind 
use of dexrazoxane following anthracycline extravasation. Despite identifying 211 
relevant papers, none were RCT’s and only one was considered eligible for evaluation 
being classified level 2c evidence (OCEBM 2009). 
 
Whilst there were many articles reviewing the literature on extravasation management 
techniques, few of these gave any inclusion or exclusion criteria for the literature 
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reviewed or evidence how the literature was critically appraised, with the majority of 
recent publications being case reports, selective reviews or ‘expert’ opinion (EONS 
2007, Schulmeister 2011a).  
 
There were also numerous papers detailing single cases often with multiple 
management strategies used, making the results unreliable and inconclusive.  
 
Taking these limitations into account, any paper graded OCEBM (2011) level 4 or 
above was included for evaluation within the final analysis of the literature within this 
review. Excluded were any, reviews based on ‘expert’ opinion or personal judgements 
and papers detailing single case reports. As a result, of the total one hundred and eighty 
nine papers initially identified, one hundred and three were excluded as being OCEBM 
(2011) level 5 evidence. 
 
Of the remaining eighty six papers, thirty eight detailed animal studies. Whilst the use 
of controlled animal studies has historically been the basis for the evaluation of 
potential management strategies, the validity of using animal studies is limited in a 
number of ways. Firstly, animal skin differs anatomically to that of man (Dorr et al 
1980), with differences in texture, elasticity and structure of the underlying dermal 
layers resulting in cytotoxic agents having to be injected intradermally as opposed to 
subcutaneously; Also, there is a major difference in the ulceration characteristics 
between the animals used (rats, pigs, guinea pigs and mice) possibly due to the 
difference in quantity of subcutaneous fat, which would again limit the applicability of 
these studies and contribute to the conflicting results. As a result of the anatomical 
difference between animal and man, the majority of animal studies administer the 
cytotoxic agent intradermally (a shallow injection just within the skin to form a 
superficial skin bubble) as opposed to subcutaneously (a deeper injection under the 
skin, into the subcutaneous tissue layer between skin and muscle) which would more 
closely mimic an inadvertent extravasation in clinical practice. It could therefore also be 
suggested that the resulting tissue damage from an intradermal extravasation would 
naturally vary to than from a subcutaneous extravasation.  
 
It is also thought that the increased vasculature of rodent skin reduces the severity of 
ulceration (Kassner 2000), which would subsequently require the administration of a 
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higher drug concentration in order to more closely mimic a clinical injury.  However 
evidence from early clinical trials show this not to be the case with many using 
administering ID anthracyclines at a concentration much lower than that used in clinical 
practice (Cohen 1979, Dorr et al 1980a, Laurie et al 1984). The most commonly used 
concentration in animal studies is 1mg/ml, a much lower concentration than the 2mg/ml 
which is used in clinical practice (eMC Doxorubicin Rapid Dissolution, point 6) and 
volume of drug infiltrated also appears to vary between species, ranging from 0.05 mls 
– 1ml.  
 
Another limitation of animal studies is that they limit findings to purely clinical 
outcome as they are unable to evaluate outcome from the patient’s perspective, to 
evaluate level of discomfort or the impact on activities of daily life. It therefore 
becomes very difficult to directly extrapolate the results from animal studies into 
clinical practice and consequently these studies were excluded from the final review. 
 
The remaining forty eight papers were further appraised to exclude those that reported 
management of ulcerations, papers that could not be sourced but the abstract indicated 
unsuitability and text book chapters. This resulted in a total of twenty nine papers 
included in the final analysis of the evidence supporting current strategies cited for 
extravasation management. (Table 2.2)  
 
Risk of bias 
It is acknowledged that whilst every care has been taken to screen the literature in 
accordance with PRISMA guidelines and the Cochrane criteria for systematic reviews 
(Higgins and Green 2011) this process has been undertaken by a single individual and 
therefore bias can never be completely excluded. 
 
Results  
The objective of this literature review was to establish the level of evidence that 
underpins contemporary practice in the management of cytotoxic chemotherapy 
extravasation and the number of studies supporting each management strategy. It also 
aimed to investigate the prevalence of studies that explore the patient experience or 
evaluate outcome from the patient’s perspective.  
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Level of evidence 
There is a lack of clear cut scientific data with published work in this field focusing 
largely on case studies from institutions or from individuals reporting a single 
management strategy in order to validate their practice.  
   
The majority (n=18) of the twenty nine papers reviewed were level 4 evidence and 
presented studies that utilised case series design (Figure 1).  
 
Number of studies supporting each management strategy 
Of the twenty nine papers included in the final data analysis, eighteen reported on the 
use of various antidotes (Figure 2).   
 
Of interest; none of the thirty eight excluded animal studies evaluated the use of saline 
washout, all focused on the use of antidotes.  
 
Is there any evidence to clearly show one technique as being more effective than 
the other? 
No studies could be sourced that compared the use of strategies such as saline washout 
against the use of antidotes.  
 
Are there any studies published that consider outcome from the patient’s 
perspective? 
No published studies could be sourced that explored outcome from the patient’s 
perspective.  
 
Are there any studies that explore the patient experience? 
No studies could be sourced that evaluated the patient experience of extravasation 
management.   
 
Discussion 
Whilst 55% (n=103) of the initial retrieved citations (n=189) were level 5 evidence and 
therefore excluded from the final analysis, some have been used for discussion purposes 
(Perez-Fidalgo et al 2012,  Wengstrom and Margulies 2008, EONS 2007, UKONS 
2008).  
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The rationale for this being that contemporary practice appears to be guided by 
publications from national and international societies: the European Oncology Nursing 
Society (Perez-Fidalgo et al 2012, Wengstrom and Margulies 2008, EONS 2007), the 
European Society of Medical Oncology (Perez-Fidalgo et al 2012), and the United 
Kingdom Oncology Nursing Society (UKONS 2008) alongside ‘expert opinion’ from 
authors such as Langer (2000 a, b, 2001, 2006, 2007, 2008, 2009, 2010 a, b, 2012)  
Schulmeister (2005, 2007 a, b, c, d, e, 2008, 2009 a, b,  2010 a, b, c, 2011), Dougherty 
(2003, 2008, 2010, 2011) and Gault (1993, 1997). This would suggest that the 
management of extravasation continues to remain empirical and based on the expert 
views of lead opinion makers.    
 
The lack of comparative studies between the two main strategies (saline washout or 
antidotes) is explicable due to difficulty ensuring their validity and reliability, the 
multiple extraneous variables and the ethical considerations making it unfeasible to use 
a control group. Also because in order for quantitative studies of this nature to yield 
statistically valid results, the sample size requirements would be too difficult to achieve 
due to the relatively small number and sporadic occurrence of extravasation. 
Consequently, in order to accurately control the multiple extraneous variables including 
age, sex, extravasated drug, site of extravasation, volume of extravasation, drug 
concentration, various co-morbidities, time to intervention, the minimum sample size 
requirement would be huge and consequently impossible to achieve without 
undertaking an international multi-centre study or collecting data over many years. 
 
Whilst there is no clear evidence to suggest one management strategy is more effective 
than the other, all of the oncology societies (EONS, UKONS, ESMO) have published 
guidelines that favour the use of antidotes as opposed to saline washout. Perez Fidalgo 
et al (2012) stating that there is ‘scarce experience’ in the use of saline washout 
technique (p71), EONS (2007) reporting that ‘a saline flush out technique could also be 
used – but this approach requires specialist advice’ (p 23) and neither Wengstrom and 
Margulies (2008) or UKONS (2007) make any reference to the option of saline washout 
as a management strategy at all. This further upholds the opinion of Steiert et al (2011) 
that more evidence needs to be published supporting the use of saline washout 
technique as a valid alternative. 
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The main finding in this review, was the significant lack of published literature on the 
patient experience of extravasation management, with there being no published studies 
evaluating the quality of care in extravasation management, nor exploring aspects of 
care that are described as ‘good’ or ‘bad’ from the patients perspective, or detailing 
patient reported outcomes. The only outcome measure reported in the sourced literature 
was that the extravasation management strategy prevented any tissue necrosis that 
resulted in the need for surgical debridement or resection (Larson 1982, Bertelli 1994, 
Mourisden et al 2007, Steiert et al 2011).  
 
Conclusions 
Implications for practice and further research 
Due to the obvious practical and ethical considerations in undertaking RCT’s to validate 
extravasation management strategies, it is suggested that outcomes based research 
should underpin contemporary extravasation management guidelines and that all 
oncology units should monitor and report the outcome of their practice in order to 
validate the strategy used.  
 
In considering National policy aimed at improving patient experience of NHS care 
(DOH 2010b, DOH 2012a) and the views of Doyle et al (2013) that patient experience 
and opinion of how well or badly health care interventions are managed directly 
impacts on their perception of its clinical effectiveness and outcome, the current lack of 
research into the patient experience of extravasation management is an area that needs 
to be addressed.  
 
The majority of sourced papers in this literature review utilised case study methodology 
as a means of reporting and developing theory on the effectiveness of specific 
extravasation management strategies. It is suggested that further research should 
employ this methodology to explore the effectiveness of extravasation management 
strategies, as this would enable the patient experience to be contextualised in relation to 
both the clinical setting and the strategy used (saline washout or use of antidotes) and to 
reveal if these bear any relevance to patients perception of effectiveness and outcome.  
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Table 1 
Electronic search process 
Data base search & date Search terms  details Number of 
citations 
retrieved 
PubMed NCBI data base search 
last carried out on 20/05/2012 via 
http://www.ncbi.nlm.nih.gov/pubmed 
 
 
A ‘My NCBI – what’s new’ weekly alert was also 
established to source new publications as they 
appeared. This was enabled via the PubMed 
National Centre for Biotechnology Information at 
the U.S. National Library of Medicine.  
 
 
‘Chemotherapy extravasation’, ‘extravasation 
management’, ‘cytotoxic drug extravasation’ ‘cytotoxic 
extravasation injury’ 
 Search details: Chemotherapy: ("drug 
therapy"[Subheading] OR ("drug"[All Fields] AND 
"therapy"[All Fields]) OR "drug therapy"[All Fields] 
OR "chemotherapy"[All Fields] OR "drug 
therapy"[MeSH Terms] OR ("drug"[All Fields] AND 
"therapy"[All Fields]) OR "chemotherapy"[All Fields]) 
AND extravasation [All Fields] 
Extravasation [All Fields] AND ("organization and 
administration"[MeSH Terms] OR ("organization"[All 
Fields] AND "administration"[All Fields]) OR 
"organization and administration"[All Fields] OR 
"management"[All Fields] OR "disease 
management"[MeSH Terms] OR ("disease"[All Fields] 
AND "management"[All Fields]) OR "disease 
management"[All Fields]) 
 
 
These searches 
resulted in the 
retrieval of 2640, 
936, 91 and 66 
citations 
respectively. 
 
A Scopus document search was last carried out on 
20/05/2012 by accessing the database at 
http://www.scopus.com/home.url   
 
 
 
A ‘title / abstract / keywords’ search with the search 
terms:  ‘Management of extravasation AND 
chemotherapy’ was used  
This search 
identified 125 
citations. 
 
 
 
The Cochrane database of systematic reviews was 
last accessed on 25/05/2012 via its website 
http://www.thecochranelibrary.com  
 
 
 
A ‘title / abstract / keywords’ search with the search 
term of ‘cytotoxic drug extravasation’  
 
 By broadening the search term to ‘extravasation’  
 
 
No results found 
 
 
2 citations were 
retrieved from the 
database’s 7272 
records. 
 
The Embase, Cinahl data base was last accessed on 
20/05/2012 via 
http://www.library.nhs.uk/mylibrary  
 
 
 
Search terms ‘chemotherapy AND extravasation AND 
cytotoxic AND drug OR extravasation AND 
management’  
resulted in 1090 
and 347 results 
respectively 
 
The British Nursing Index (BNI) was last accessed 
on 27/05/2012 via the RCN website at 
http://www.rcn.org.uk/development/library/elibrary  
 
 
 
Search terms ‘chemotherapy extravasation’ and 
‘extravasation’ 
 
 
 
Resulted in 17 
and 39 citations 
respectively. 
 
 www.extravasation.org  last accessed on 
07/01/2012  
 
 
 
 
 
Identified 98 
citations on the 
websites 
reference list. 
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Table 2 
 Screening of the Literature  
Adapted from:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): 
e1000097. doi:10.1371/journal.pmed1000097 www.prisma-statement.org. 
 
 Records Identified through database searching 
 
Additional records identified through other sources Total number of texts 
initially identified 
 
1. Identification of the 
literature 
 
PubMed NCBI data base searches were last carried out on 20/05/2012 via 
http://www.ncbi.nlm.nih.gov/pubmed using the search terms: 
‘Chemotherapy extravasation’, ‘extravasation management’, ‘cytotoxic 
drug extravasation’ ‘cytotoxic extravasation injury’.  
resulting in the retrieval of 2640, 936, 91 and 66 citations respectively 
 
A Scopus document search was last carried out on 20/05/2012 by 
accessing the database at http://www.scopus.com/home.url  A ‘title / 
abstract / keywords’ search with the search terms:  ‘Management of 
extravasation AND chemotherapy’ was used and this search identified 
125 citations. 
 
The Embase, Cinahl data base was last accessed on 20/05/2012 via 
http://www.library.nhs.uk/mylibrary using the search terms 
‘chemotherapy AND extravasation AND cytotoxic AND drug OR 
extravasation AND management’ resulting in 1090 and 347 results 
respectively.  
 
The British Nursing Index (BNI) was last accessed on 27/05/2012 via the 
RCN website at 
http://www.rcn.org.uk/development/library/elibrary using the search 
terms ‘chemotherapy extravasation’ with a resulting 17 citations sourced 
and ‘extravasation’ which resulted in 56 citations  
 
The Cochrane database of systematic reviews was last accessed on 
25/05/2012 via its website http://www.thecochranelibrary.com and a ‘title 
/ abstract / keywords’ search with the search term of ‘cytotoxic drug 
extravasation’ produced no results. By broadening the search term to 
‘extravasation’ 2 citations were retrieved from the database’s 7272 
records. 
 
 
 
 
 
 
 
 
A search was also undertaken by accessing 
www.extravasation.org on 07/01/2012 which identified 98 
citations on the websites reference list. 
 
A further 71 sources were added during the search for full texts 
and following a hand search through the bibliographies of 
retrieved texts. 
 
5,539 texts originally 
identified. 
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 Removal of duplicates and sources not published in English 
 
Records to be  screened Indexed  texts 
2. Screening process 
 
i. Language and relevance 
 
ii. Duplicates 
 
Following screening for language and relevance of the 3733 PubMed 
sourced citations these were combined into an alphabetical PubMed 
bibliography by author, so allowing for duplicates to be identified and 
removed. This resulted in 297 PubMed citations saved prior to 
assessment of eligibility for inclusion in the final data synthesis.   
 
Of the 125 Scopus results 43 were saved following screening as detailed 
above. 
 
The Embase, Cinahl citations combined, filtered for duplicates and 
further filtered for citations not published in English resulted in 271 
citations saved for eligibility screen. 
 
The citations accessed from the BNI were filtered for duplicates and 
sources not directly translated into English resulting in 54 citations. 
 
Of the 2 results sourced from the Cochrane library, only one related to 
intravenous extravasation management and was saved for further 
eligibility review.  
 
All sources were then amalgamated and further filtered for 
duplicates. 
 
This resulted in 351 citations indexed for eligibility screening. 
 
351 Texts to be screened 
for eligibility 
 Full text excluded Texts unable to be obtained Full text assessed for 
eligibility 
 
3. Eligibility 
 
Exclusion and inclusion 
criteria as specified in main 
text 
 
Using the specified criteria as described 141texts were excluded as not 
relevant to the literature review. 
 
 
 
A further 31 texts could not be sourced from Med-line, Cinahl, 
the RCN database, Scopus or via the post graduate library 
services and were excluded on the basis of the abstract or title. 
 
 
Of the final 189 texts identified for inclusion review 23 were 
unable to be sourced (December 2012). 
 
 
 
 
 
 
179 texts were initially 
included for as eligible for 
review. 
 
A further 10 texts were 
sourced through data base 
alerts and ongoing 
bibliography searches. 
 
 
 Literature included in final review Literature excluded from final review Total to be included in 
final analysis 
4. Included texts 
 
Eligibility criteria for papers included in the final data analysis was any 
paper OCEBM Level 4 and above  
 
 
Excluded were all animal studies irrespective of OCEBM 
grading, non systematic reviews, reviews based on expert 
opinion or personal judgements and papers detailing single case 
reports as these were all graded level 5 based on OCEBM (2011) 
criteria. 
 
 
29 texts identified as 
eligible for inclusion in 
the final analysis  
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Figure 1: Levels of evidence 
0
20
40
60
80
100
120
140
160
180
Level 1 
Evidence
Level 2 
Evidence
Level 3 
Evidence
Level 4 
Evidence
Level 5 
Evidence
Unknown as 
unable to 
source
 
 
 
Figure 2: Number of papers sourced reporting an individual strategy 
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Table 3: Literature included in the final analysis 
 
WATCH AND WAIT / ICE AND ELEVATE / CONSERVATIVE MEASURES 
Date of 
publicati
on 
Reference Hypothesis / aim of study Study design  / intervention Sample size and level 
of evidence  
(OCEBM 2011)  
 
Main Findings 
(Appraised using PICO or CASP dependant on study design) 
 1982 
 
Larson DL. Treatment of 
tissue extravasation by 
antitumor agents. Cancer. 
1982 May 1; 49(9):1796-9.  
 
 
 
The application of ice inactivates 
the locally destructive effects of 
doxorubicin.  
 
 
 
Design 
Case series report detailing 
the immediate treatment of 
50 extravasations occurring 
over a 20 month period 
 
Intervention 
ICE AND ELEVATE.   
  
Report on 50 patients 
treated over a 20 
month period using  
‘watch and wait’ 
 
OCEBM Level 4 
 
First example of vasoconstriction as a management technique cites recent 
studies personally communicated by Dorr as evidence  
 
1. Clearly focused research question 
To find a simple and predictable management strategy as use of antidotes 
remains theoretical and unpredictable. Use of immediate surgery is again 
anecdotal and unproven. 
2. The method used was a detailed review of all cases of extravasation (n=50) 
within a 20 month period, which was appropriate to answer the question 
posed. 
3. No explicit detail of the 50 cases – just says 50 patients receiving 
doxorubicin or Vincristine. 
4 – 7. No detail of any of the extravasation injuries, no outcomes, no 
confounders 
 
Presents only one case study out of 50 
 
Patients seen by plastic surgeon within 72 hours. If no further deterioration 
over 10 days then usually ok, if pain then usually go on to require surgical 
excision. 
States that only 12 of the 50 patients seen required surgery (less than 1/3). 
Quoted by Schulmeister 2007 stating 1/3 of patients went on to require 
surgery.                                              
 
  
Not precise, no measurable evidence States the main indication to proceed to 
surgery is pain and convincing the patient to the risk of infection 
Impossible to evaluate the results 
In the methods section it states that no drugs are given locally, but in the 
single case report it states that the patient was given 50mg s/c prednisolone. 
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Date  Reference Hypothesis / aim  Study design  / intervention Sample size and level 
of evidence  
(OCEBM 2011)  
 
Main Findings 
(Appraised using PICO or CASP dependant on study design) 
 1985 
 
Larson DL. What is the 
appropriate management of 
tissue extravasation by 
antitumor agents? Plast 
Reconstr Surg. 1985 Mar; 
75(3):397-405.  
 
 
 
 
 
Considers pain, usually associated 
with varying degrees of skin 
involvement, to be the only 
indication for surgery  
Advocates ice and elevate 
 
 
 
 
 
 
 
               
Design                                  
Case series reports 
Intervention                              
ICE and ELEVATE 
                    
Data collected on 175 
patients 
 
OCEBM – Level 4 – 
case series as no 
follow up 
Seminal article widely quoted as the largest clinical study on 
extravasation to date (according to Kennedy 2003) 
 
1. Does have a clearly defined research question 
2. Method used to answer the question was appropriate 
3. Representative cohort of patients – all who attended with extravasation 
injuries 
4.No detail of type of drug involved in extravasation – general overview in 
table with no figures 
5. Objective measurement of outcome – either did or didn’t require surgery 
6.No consideration of confounding factors – size of extravasation, type of 
drug, time to treatment etc 
7 No definitive follow up period 
 
Results 
Most of the paper is discussion about alternative options that have been 
proposed in the literature States that up to 1984 no less than 15 antidotes have 
been investigated in animal studies, but that they report a small number of 
cases treated in a variety of ways 
No clear detail. States that 89% patients responded to ice and elevate 
Supports his previous publication  of case reports in 1982 
Reports on 4 cases of vinca alkaloids that required excision and grafting  
 
 2002 
 
Langstein HN, Duman H, 
Seelig D, Butler CE, Evans 
GR. Retrospective study of 
the management of 
chemotherapeutic 
extravasation injury. Ann 
Plast Surg 2002 Oct;49(4): 
369-74  
 
 
 
 
 
 
Most cases of extravasation can be 
managed conservatively, with 
directed surgical treatment of the 
ulceration when appropriate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Design 
Retrospective Case Series 
Analysis 
 
Intervention 
Conservative - Watch and 
wait 
 
 
 
 
44 cases over 6 years 
 
OCEBM – Level 4 
 
Retrospective study  
Advocates ‘watch and wait’ conservative treatment, followed by surgical 
debridement if deemed necessary, Paclitaxel and doxorubicin were the 2 most 
common drugs 
Only 26 of 42 patients required plastics referral and only 10 of the 26 required 
surgical intervention / debridement 
Mean time of injury to referral was 40 days 
 
 
Approx 25% of patients requiring surgery 
In 2 patients, partial skin graft loss developed and secondary epithelialisation 
caused slight limitations in range of motion.  
 
One patient who was treated with incision and drainage died of fungal sepsis. 
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SUBCUTANEOUS OR TOPICAL CORTICOSTEROIDS +/- SODIUM THIOSULPHATE 
Date  Reference Hypothesis / aim of study Study design  / intervention Sample size and level 
of evidence  
(OCEBM 2011)  
 
Main Findings 
(Appraised using PICO or CASP dependant on study design) 
 1979 
 
Barlock AL, Howser DM, 
Hubbard SM. Nursing 
management of adriamycin 
extravasation.  Am J Nurs. 
1979 Jan; 79(1):94-6.  
 
Corticosteroids will reduce the 
severe inflammatory response from 
doxorubicin extravasation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Design 
Prospective randomised 
study with all patients given 
doxorubicin  included 
 
Intervention 
S/C HYDROCORTISONE 
SODIUM SUCCINATE 
FOLLOWED BY TOPICAL 
HYDROCORTISONE 
CREAM, ICE AND 
ELEVATE 
 
 
 
 
 
 
 
 
 
 
 
Small sample size n=9 
 
OCEBM Level 2 
graded down to Level 
3 ( no control arm and 
very small study size)  
P – 139 included, but only 9 evaluated as extravasations 
I - Group A – IV hydrocortisone sodium succinate (via cannula used to 
administer chemo) followed by topical ice pack x 5 pts. 
I - Group B – Cannula removed and hydrocortisone sodium succinate given 
ID and S/C by multiple inj around the extravasation site x 4 pts. Then – 1% 
hydrocortisone cream applied and area covered with gauze 
C – No control arm 
O - Neither group went on to develop skin necrosis or ulcers but those in 
group A did have pain and erythema, with loss of patency in the vein.   
Appraisal 
R – No detail of how subjects were randomised 
No reference to variables 
A – Some patients had additional steroids 
M – not blinded 
 
Randomised trial, but no control arm 
No indication of how patients were randomised to arm A or B.  
No control group 
Still = pain at site requiring analgesia 
Unknown volume or size of extravasation 
 
Valid as a general discussion only.                                                                          
 
1992 
 
Tsavaris NB, 
Komitsopoulou P, 
Karagiaouris P, Loukatou 
P, Tzannou I, Mylonakis 
N, Kosmidis P. Prevention 
of tissue necrosis due to 
accidental extravasation of 
cytostatic drugs by a 
conservative approach. 
Cancer Chemother 
Pharmacol. 1992; 
30(4):330-3.  
 
 
Aim: To evaluate comparatively the 
effectiveness of a conservative 
approach to treatment, using two 
therapeutic schedules (with and 
without sodium thiosulfate  
 
 
 
 
 
 
 
 
 
 
 
Design 
Case control - Comparative 
Study 
 
Intervention 
HYDROCORTISONE AND 
DEXAMETHASONE vs 
SODIUM THIOSULPHATE  
plus HYDROCORTISONE 
AND DEXAMETHASONE 
 
 
63 patients 
 
OCEBM – Level  3 
 
 
 
1. Clearly focused issue 
2. Appropriate method used to answer the question 
3.Clearly defined recruitment process with eligibility criteria 
No power calculation and no explanation of time frame (5 years) 
4. doesn’t specify how group A or group B were chosen 
5. Measurement of outcome was objective and by specified methods 
6. No consideration of any confounders - Various extravasated drugs – all 
vesicants  
7. Outcome 
The mean healing time for group B, which received ST was about half that for 
group A, which did not. – 
Concluded the application of conservative measures during chemotherapy 
may prevent tissue necrosis that 
Low precision of results  
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DMSO 
Date  Reference Hypothesis / aim of study Study design  / intervention Sample size and level 
of evidence  
(OCEBM 2011)  
 
Main Findings 
(Appraised using PICO or CASP dependant on study design) 
 1983           
 
Olver IN, Schwarz MMA. 
Use of dimethyl sulfoxide 
in limiting tissue damage 
caused by extravasation of 
doxorubicin. Cancer Treat 
Rep. 1983 Apr; 67(4):407-
8.  
 
DMSO as an anti-inflammatory free 
radical scavenger will help promote 
healing.. 
 
 
 
Design 
Case reports 
 
Intervention     DMSO for 
Doxorubicin extravasations 
However also used ice and 
also used sodium bicarbonate    
 
3 case reports 
 
OCEBM – Level 4  
 
Limited detail 
Mixed management strategy 
Outcome measured at different time frame 
 
Not true case studies 
Inconclusive 
 
 
1987 
 
Ludwig CU, Stoll HR, 
Obrist R, Obrecht JP. 
Prevention of cytotoxic 
drug induced skin ulcers 
with dimethyl sulfoxide 
(DMSO) and alpha-
tocopherole. Eur J Cancer 
Clin Oncol. 1987 Mar; 
23(3):327-9.  
Both DMSO and alpha-tocopherol 
(vitamin E) are free radical 
scavengers. DMSO is an anti-
inflammatory free radical scavenger 
that is purported to help promote 
healing, whilst vitamin E is thought 
to protect against highly reactive 
radicals. 
 
 
Design 
Clinical pilot study using 
case series methodology 
 
Intervention 
DMSO and ALPHA-
TOCOPHEROLE Topically 
for anthracyclines and 
Mitomycin extravasations 
 
 
Small sample size  
(n = 8) 
 
OCEBM Level 4 
 
1. Clinical pilot study to evaluate the effectiveness of DMSO and a-
tocopherol for doxorubicin or mitomycin extravasation 
2. Case series is the most appropriate way to address the problem due to the 
sporadic and low incidence rate 
3. All patients that presented with a extravasation during an explicit time 
period were recruited 
Specific inclusion criteria 
4. Allowed for adequate follow up – until resolution of symptoms 
 
Not possible to eliminate all extraneous variables due to limited number 
included in study, however the patient group is a proper reflection of those in 
clinical practice and the drug concentrations are standard for clinical practice 
(2mg / ml) 
 
Positive results 
 
1988 
  
Olver IN, Aisner J, Hament 
A, Buchanan L, Bishop JF, 
Kaplan RS. A prospective 
study of topical dimethyl 
sulfoxide for treating 
anthracycline 
extravasation. J Clin 
Oncol. 1988 Nov; 
6(11):1732-5.  
DMSO is an anti-inflammatory free 
radical scavenger that is purported 
to help promote healing 
 
 
 
 
 
Design                                  
Single arm study (pilot 
study)  
 
Intervention                         
DMSO 6 hourly x 14 days 
 
 
20 patients recruited in 
a prospective study  
 
OCEBM – Level 3 
 
P- 20 patients recruited in a prospective study 
I- DMSO for anthracycline extravasation 
C- No control group – would have been unethical 
O- Effective antidote 
 
R- No randomisation – all included 
A- All treated equally and all accounted for 
M-All observed for 3 months apart from 2 who died and 2 who were lost to 
follow up 
 
Outcome 
Clearly focused question with outcome objectively measured.  
No patients progressed to ulceration or required surgical intervention 
Valid results 
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Date of 
publicati
on 
Reference Hypothesis / aim of study Study design  / intervention Sample size and level 
of evidence  
(OCEBM 2011)  
 
Main Findings 
(Appraised using PICO or CASP dependant on study design) 
1989            
 
Lawrence HJ, Walsh D, 
Zapotowski KA, Denham 
A, Goodnight SH, Gandara 
DR. Topical 
dimethylsulfoxide may 
prevent tissue damage 
from anthracycline 
extravasation. Cancer 
Chemother Pharmacol. 
1989; 23(5):316-8.  
 
DMSO is an anti-inflammatory free 
radical scavenger that is purported 
to help promote healing 
 
 
 
Design 
Prospective case series 
 
Intervention 
ICE, LOCAL 
GLUCOCORTICOID 
INJECTION, AND 
DIMETHYLSULFOXIDE 
(DMSO) 55%-99% applied 
topically every 2-4 h after 
extravasation for a minimum 
of 3 days 
 
 
case series reports of 4 
patients 
 
OCEBM – Level 4 
 
1. Aimed to report on the efficacy of DMSO in preventing tissue necrosis 
following anthracycline extravasation 
2.Case series is appropriate for non animal studies 
3. 4 consecutive cases of anthracycline extravasation 
4. No control arm 
 
 
Limited validity in supporting use of DMSO due to mixed management 
strategy therefore could dispute the effect, plus no specifics given as to length 
of follow up and no confounding factors accounted for 
 
1994 
 
St Germain B, Houlihan N, 
D'Amato S. Dimethyl 
sulfoxide therapy in the 
treatment of vesicant 
extravasation: two case 
presentations. J Intraven 
Nurs. 1994 Sep-
Oct;17(5):261-6.  
Free radical scavenger 
 
 
 
Design 
case studies 
 
Intervention 
DMSO 
 
 
 
Only 2 Patients 
 
OCEBM – Level 4/5 
 
Very small sample size 
Limited validity 
 
 
 
1995 
 
 
 
Bertelli G, Gozza A, Forno 
G, Vidili M, Silvestro S, 
Venturini M, Del Mastro 
L, Garrone O, Rosso R, 
Dini D. Topical 
dimethylsulfoxide for the 
prevention of soft tissue 
injury after extravasation 
of vesicant cytotoxic 
drugs: a prospective 
clinical study. J Clin 
Oncol. 1995 Nov; 
3(11):2851-5.  
 
Aim: To evaluate the activity and 
tolerability of dimethylsulfoxide 
(DMSO) a free radical scavenger in 
the prevention of soft tissue toxicity 
after extravasation of cytotoxic 
drugs 
 
 
Design                                 
Open Prospective Study 
using case series 
methodology 
Intervention                         
DMSO 
 
 
 
 
144 patients with 
extravasations 
127 entered in study 
doxorubicin (n = 11) 
epirubicin (n = 46) 
mitomycin (n = 5) 
mitoxantrone (n = 13) 
Cisplatin (n = 44) 
Carboplatin (n = 6) 
ifosphamide (n = 14)  
fluorouracil (n = 5) 
  
OCEBM – Level  3 
 
Topical 99% DMSO applied 
Only one patient ulcerated  
 
Multiple drugs therefore many variables not accounted for  
 
Cited by Langer et al 2000b as being limited in design as the study had no 
control arm (however as this was a clinical study having a control arm would 
have been unethical!) 
 
Appears to show valid results  
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Date of 
publicati
on 
Reference Hypothesis / aim of study Study design  / intervention Sample size and level 
of evidence  
(OCEBM 2011)  
 
Main Findings 
(Appraised using PICO or CASP dependant on study design) 
1996 
 
Bonnetblanc JM, 
Bordessoule D, Fayol J, 
Amici JM. Treatment of 
accidental extravasation of 
antitumor agents with 
dimethylsulfoxide and 
alpha-tocopherol. Ann 
Dermatol Venereol. 1996; 
123 (10):640-3.  
Hypothesis 
Free radical scavenger 
 
 
 
Design 
Open prospective study using 
case series methodology 
 
Intervention 
DMSO and A-Tocopherol 
 
 
 
10 patients 
 
OCEBM - Level 4 
 
Absence of secondary ulcerations and the preservation of the implant sites 
 
Doesn’t specify nature of extravasated drugs in the abstract 
 
positive results 
 
 
 2004 
 
DeLemos M.L. Role of 
Dimethylsulphoxide for 
management of 
chemotherapy 
extravasation. J Oncol 
Pharm Pract December 
2004 vol. 10 no. 4 197-200  
 Extravasation of anthracyclines is a 
rare complication that can lead to 
severe tissue necrosis and 
ulceration. With conservative 
measures (e.g., limb elevation, 
cooling), ulceration may develop in 
28% of patients. Topical 
dimethylsulfoxide is commonly 
suggested as an antidote. However, 
there are inconsistent and 
sometimes conflicting animal data 
on its efficacy and safety 
 
 
 
Design 
Review based on 2 clinical 
studies (n=147) following a 
database search with explicit 
criteria 
 
Intervention 
DMSO 
 
 
147 patients 
 
Presented as a 
review, but  not 
upheld by OCEBM 
Appraisal criteria as 
level 1therefore 
graded as level 2 
 
 
Doesn’t give a focused research question  
‘The following review will assess the clinical evidence on the use of DMSO’ 
 
F = Search Strategy:  
 Ovid Medline (1966 to April 2004) was searched using the medical subject 
headings of ‘Dimethyl Sulphoxide’ and ‘Extravasation of Diagnostic and 
Therapeutic Materials’, and limited to English language and human articles. 
No ‘results’ section  
No outline of the number of titles and abstracts reviewed, the number of full-
text studies retrieved, or the number of studies excluded together with the 
reasons for exclusion.  
 
A No inclusion or exclusion criteria 
A Inclusion criteria appears to be papers with more than 10 patients in the 
study 
Only two case series included more than 10 patients 
 
Results presented as a table 
 
Indicates DMSO to be a well tolerated effective management strategy to 
prevent ulceration 
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HYALURONIDASE 
Date  Reference Hypothesis / aim of study Study design  / intervention Sample size and level 
of evidence  
(OCEBM 2011)  
 
Main Findings 
(Appraised using PICO or CASP dependant on study design) 
1994 
 
Bertelli G, Dini D, Forno 
GB, Gozza A, Silvestro S, 
Venturini M, Rosso R, 
Pronzato P. Hyaluronidase 
as an antidote to 
extravasation of Vinca 
alkaloids: clinical results. J 
Cancer Res Clin Oncol. 
1994;120(8):505-6.  
Hyaluronidase will aid reabsorbtion 
 
 
Design 
Case series (prospective) 
 
Intervention 
HYALLURONIDASE FOR 
VINCA’S 
 
 
 
 
 
7 patients 
 
OCEBM  - Level 4 
 
A. Appropriate method for the question asked 
All cases of vinca alkaloid extravasation recruited, but no explanation of time 
frame or sample size 
No control as unethical 
Subjective measurement / very vague 
No confounders accounted for – dose, volume, drug etc 
B Positive results but small sample size 
Follow up time – not specific 
C. Outcome – favourable 
 
 
1996 
 
Du Bois, A., Fehr, M. K., 
Bochtler, H., & Koechli, 
O. R. (1996). Clinical 
course and management of 
paclitaxel extravasation. 
Oncology Reports, 3(5), 
973-974. 
Hyaluronidase will aid reabsorbtion 
of the extravasated drug 
 
 
 
Design 
Case control study 
 
 
Intervention 
APPLICATION OF ICE +/-
HYALURONIDASE for 
paclitaxel extravasation 
 
 
 
 
4 cases 
 
OCEBM - Level 4 
 
Small sample size therefore limited validity 
 
Negative results 
Found that hyaluronidase increased the time to healing 
 
1997  
 
Bertelli G, Cafferata MA, 
Ardizzoni A, Gozza A, 
Rosso R, Dini D, Dorr RT. 
Skin ulceration potential of 
Paclitaxel in a mouse skin 
model in vivo. Cancer June 
1, 1997; 79 (11): 2266-68  
Hypothesised that if hyaluronidase 
was shown beneficial in a mouse 
skin model this should translate into 
clinical practice 
 
 
 
 
 
 
 
 
 
 
 
 
 
Design 
case series - correspondence 
 
Intervention 
 
HYALURONIDASE 
 
 
7 patients - 5 x 
paclitaxel 
                 - 2 x 
docetaxel 
 
OCEBM – Level 4/5 
 
 
A Clearly focused issue 
Describes clinical data gathered on 7 patients 
Clinical observation - Appropriate method to appraise  outcome in clinical 
practice 
Recruited as the event occurred dependant on extravasated drug 
7 patients - 5 x paclitaxel 
                  - 2 x docetaxel 
Confounders not taken into consideration 
Unsuitable for control arm - unethical 
B Positive results 
Agrees with Dorr on use of hyaluronidase as an antidote. 
Followed up for 21 weeks 
C Clinically relevant, but small sample size and just correspondence as 
opposed to a reported clinical study 
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DEXRAZOXANE 
Date  Reference Hypothesis / aim of study Study design  / intervention Sample size and level 
of evidence  
(OCEBM 2011)  
 
Main Findings 
(Appraised using PICO or CASP dependant on study design) 
2006  
 
Frost A, Gmehling D, 
Azemar M, Unger C, 
Mross K. Treatment of 
anthracycline extravasation 
with dexrazoxane -- 
clinical experience. 
Onkologie. 2006 Jul; 
29(7):314-8. Epub 2006 Jul 
3. 
To demonstrate that the treatment of 
anthracycline extravasation with 
dexrazoxane is potentially useful 
and safe. 
 
 
 
 
 
 
 
Design                                       
Case reports 
Intervention 
DEXRAZOXANE 
 
  
3 CASE REPORTS 
3 cases of 
extravasation with 3 
different 
anthracyclines.                 
2 pts treated with 
dexrazoxane 
 
OCEBM – Level 4 
 
Positive results – no surgery, but the small sample size limits validity of 
results 
 
 
 
2007 
 
Mouridsen HT, Langer 
SW, Buter J, Eidtmann H, 
Rosti G, de Wit M, 
Knoblauch P, Rasmussen 
A, Dahlstrøm K, Jensen 
PB, Giaccone G. 
Treatment of anthracycline 
extravasation with Savene 
(dexrazoxane): results from 
two prospective clinical 
multicentre studies. Ann 
Oncol. 2007 Mar; 
18(3):546-50. Epub 2006 
Dec 21.  
Aim:To assess the efficacy and 
tolerability of  dexrazoxane  as an 
acute antidote in biopsy-verified 
anthracycline extravasation. 
 
 
 
 
 
Design 
Two prospective, open-label, 
single-arm, multicentre 
studies 
 
Intervention 
DEXRAZOXANE 
 
 
Study 1 = 18 patients 
assessed for efficacy 
and 23 for safety 
Study 2 = 36 for 
efficacy and 57 for 
safety 
Total = 53 patients 
 
OCEBM -  Level 2 / 3 
 
P- Study 1 = 18 patients assessed for efficacy and 23 for safety 
Study 2 = 36 for efficacy and 57 for safety 
I- Use of dexrazoxane for anthracycline extravasation 
C- no control group for comparison, the results were judged against ‘standard 
practice’ supposed to be surgery = historical control 
O- prevention of surgical debridement in all but one patient of the total 53 
assessed 
However there were also grad 2-4 lab based toxicities = myelosuppression 
and raised liver enzymes 
R- no randomisation = cohort study 
A- all patients accounted for 
M- debatable as to the objectivity of measurements. No strict reporting 
criteria, clinical evaluation was vague. Subjective in reporting adverse events  
 
Outcome 
53 patients all treated within 6 hours 
Extravasation verified by biopsy 
Only 1 required surgical intervention  
= positive outcome with valid results 
 
 
2008 
 
Hasinoff  BB.  The use of 
dexrazoxane for the 
prevention of anthracycline 
extravasation injury. 
Expert Opin Investig 
Drugs. 2008 Feb; 
17(2):217-23.  
Aim: to evaluate the preclinical and 
clinical literature on the use of 
dexrazoxane in preventing 
anthracycline-induced extravasation 
injury.                                  
 
Design 
Review 
 
 
Intervention 
DEXRAZOXANE 
 
 
OCEBM Level 
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Date of 
publicati
on 
Reference Hypothesis / aim of study Study design  / intervention Sample size and level 
of evidence  
(OCEBM 2011)  
 
Main Findings 
(Appraised using PICO or CASP dependant on study design) 
 2008 
 
Langer SW. Treatment of 
anthracycline extravasation 
from centrally inserted 
venous catheters. Oncol 
Rev 2008; 2:114-116 
Aim: To present data on 7 cases of 
Savene treatment of anthracycline 
extravasations from central venous 
catheters. 
 
 
 
Design 
Case series methodology 
 
Intervention 
DEXRAZOXANE 
7 x Cases  
 
OCEBM – Level 4 
Clearly addressed issue 
Appropriate method to answer the question 
Uses 4 cases of CVC extravasation as detailed in the prospective studies 
reported by Mourisden et al (2007) of which Langer was a co-author and 3 
from the literature 
Gives no indication of how the 3 cases were sourced 
No inclusion / exclusion criteria for searching the literature 
= potential for selection bias 
Limits validity of results 
Positive outcomes but... 
However the report does include 1 patient who went on to experience tissue 
necrosis at extravasation site 
 
2011 
 
Fontaine C, Noens L, 
Pierre P, DeGreve J                
Savene (Dexrazoxane) Use 
in Clinical Practice                 
Support Care Cancer. Short 
communication. Published 
on line Springer-Verlag           
DO1 10.1007/s00520-012-
1382-2 27/01/2012 
 
 
Aim: To assess, in clinical practice, 
the efficacy and safety profile of 
Savene® for ACEV in different 
Belgian hospitals 
  
 Design 
Survey methodology using a 
retrospective questionnaires  
 
Intervention 
DEXRAZOXANE 
Questionnaire sent to 
44 hospitals resulting 
in data on 41 patients 
 
OCEBM – Level 4 
 
 
 
 
P – 41 patients identified and included in results 
28 had extravasation of an anthracycline from a CVC 
I – All treated with dexrazoxane 
C - Historically controlled study with need for surgical debridement as 
the ‘control’ 
O – generally positive outcome 
 
R – No randomisation as historical data from questionnaires 
A – Both peripheral and CVC extravasations , all treated equally 
M – Retrospective questionnaire, but limitations acknowledged 
 
Outcome In two patients, surgical debridement was unavoidable due to 
extensive infiltration of anthracyclines in the surrounding tissue. The 
scheduling of the planned chemotherapy courses could be maintained in 30 of 
41 patients (73%). 
Eight adverse events of haematological toxicity 
One Wound infection 
Surgical intervention avoided in 92.9% cases 
 
Valid results 
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Date  Reference Hypothesis / aim of study Study design  / intervention Sample size and level 
of evidence  
(OCEBM 2011)  
 
Main Findings 
(Appraised using PICO or CASP dependant on study design) 
2012 Drake D. Emergency 
Management of 
Anthracycline 
Extravasation. 
Emerg Med J September 
2012; 29 (9): 777 – 779 
Downloaded from 
emj.bmj.com on August 
26, 2012 - Published by 
group.bmj.com 
Aim: To establish whether 
intravenous dexrazoxane reduces 
the risk of tissue necrosis after 
extravasation of the chemotherapy 
agent anthracycline.  
Design 
Short cut review 
 
Intervention 
DEXRAZOXANE 
OCEBM  Level 1 
 
Clearly defined research question 
In (an adult presenting with peripheral anthracycline extravasation) will 
(treatment with intravenous dexrazoxane reduce the risk of soft tissue 
necrosis)? 
Clearly defined search strategy 
 
No specific inclusion / exclusion criteria   
 
However appears to be only papers graded 2 or above as the article by 
Mourisden (2007) was the only one included as all of the others were below 
level 2  Graded it a level 2c  and from this one study deduced that there was 
promising evidence for dexrazoxane use 
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SALINE WASHOUT 
Date  Reference Hypothesis / aim of study Study design  / intervention Sample size and level 
of evidence  
(OCEBM 2011)  
 
Main Findings 
(Appraised using PICO or CASP dependant on study design) 
1993  
 
Gault D.T Extravasation 
Injuries British Journal of 
Plastic Surgery. 1993;  46: 
p91-96 
 
 
Rather than leave potentially 
harmful drugs to remain in the 
subcutaneous and perivenous space 
it is suggested preferable to 
physically remove the drug by 
flushing the area through with 
sterile saline 0.9%.  
 
 
 
 
Design 
Retrospective case series 
review 
 
Intervention 
SALINE WASHOUT 
 
 
96 patients 
 
OCEBM – Level 4 
 
1. Doesn’t ask a question, but presents alternative techniques for extravasation 
management 
2.Recruited all patients who experienced an extravasation 
3. Varying drugs, not all cytotoxics, no confounding factors taken into 
account 
4. outcome appraised on need for further surgical intervention 
5. assessment made on the 44 patients referred early 
37 patients had saline washout alone 
6. No explanation of why some had liposuction, some had SWOT and some 
had both 
Outcome - of the 44 patients treated with SWOT 39 had no further tissue 
damage (88.5%) the other 5 had minor skin blistering or delayed healing. 
None required surgical debridement 
Doesn’t state how many of these patients had anthracycline extravasations 
positive results as no surgery required 
Not very precise results but still significant 
 1994 
 
Scuderi N, Onesti MG. 
Antitumor agents: 
extravasation, 
management, and surgical 
treatment. Ann Plast Surg. 
1994 Jan;32(1):39-44 
Saline will wash the drug out of the 
tissues and steroids to reduce 
inflammation 
 
. 
Design 
Cohort study 
 
Intervention 
EARLY SURGERY                   
SALINE INJECTED AT 
SITE 20-90mls  PLUS 
CORTICOSTEROIDS 
 
 
 
 40 patients                      
 
OCEBM  – Level   3 / 
4 
 
 
Appropriate method for the question asked 
40 patients out of 52 referred – reason as to why only these 40 were chosen is 
cited as tumour type and extravasated drug. 
3 patients excluded from results as late presentation (2 weeks post 
extravasation) 
 Injected with s/c saline volume dependant on site 
 No control group (but this would have been unethical) 
B. Superficial ulceration cleared within 10-14 days and no residual injury in 
any patient. All were followed up for between 6-18 months  
Takes no account of confounders ie those also treated with topical steroids 
Varying number of treatments with s/c saline from 3 – 6 applications – no 
rationale given as to why  
C. Outcome =   3 of 26 pts required surgery for deep tissue damage  
very vague descriptors, how outcome was measured etc 
 2000 
 
 Cicchetti S, Jemec B, Gault 
DT. Two case reports of 
vinorelbine 
extravasation: 
management and review 
of the literature. Tumori. 
2000 Jul-Aug; 
86(4):289-92.  
Hypothesis 
Hyaluronidase to open up 
connective tissue followed by saline 
to wash the drug from the tissue 
 
Design 
Case Reports 
 
Intervention 
HYALURONIDASE AND 
SALINE WASHOUT 
 
 
 
 
2 Patients 
 
OCEBM – Level 4 
 
Reports positive results with no surgery required 
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Date  Reference Hypothesis / aim of study Study design  / intervention Sample size and level 
of evidence  
(OCEBM 2011)  
 
Main Findings 
(Appraised using PICO or CASP dependant on study design) 
 2002 
 
Khan MS, Holmes JD. 
Reducing the morbidity 
from extravasation injuries. 
Ann Plast Surg. 2002 Jun; 
48(6):628-32; discussion 
632.  
Hypothesis 
Based on Gault’s flushout 
hypothesis 
 
Design 
Case Series 
 
Intervention 
SALINE WASHOUT 
 
 
18 Patients 
 
OCEBM – Level  3/4 
 
1. Clearly focused issue = reducing morbidity from an extravasation  injury 
2. Case series is the most appropriate means of addressing this issue in 
clinical practice 
3. recruited within a specific time frame = 18 over 2 years from 97-99 
4/5 All extravasations included. Not enough detail about outcome measures 
therefore allowing for bias, subjective 
No control arm 
6. Seven extravasations were  anthracyclines (1/3rd) 
7. 6 month follow up 
8 / 9 However 17 of the 18 patients had no untoward sequalae and the 1 
patient who required surgical intervention was not treated within the protocol. 
Followed up for 6 months 
Intervention based on Gault’s flushout technique 
Valid results 
2005  
 
Napoli P, Corradino B, 
Badalamenti G, Tripoli M, 
Vieni S, Furfaro MF, 
Cordova A, Moschella F. 
Surgical treatment of 
extravasation injuries. J 
Surg Oncol. 2005 Sep 15; 
91(4):264-8; discussion 
268-9. 
Aim: The authors present their 
experience of treating anti-cancer 
drug extravasation by means of a 
composite surgical technique that 
consists of infiltration with 
physiological solution and 
hyaluronidase and subsequent 
manual aspiration of solutes 
alternated with profuse irrigation of 
the infiltrated area.  
Design 
Report 
 
 
Intervention 
SALINE INFILTRATION, 
LIPOSUCTION AND 
WASHOUTWASHOUT 
 
 
 
25 Patients 
OCEBM – Level    4 / 
5 
 
 
Explains the procedure of saline infiltration, liposuction and then washout, but 
gives no specific detail on individual patients, nature of the extravasated drug 
or specific measurement of outcome 
 
States that since the year 2000 this technique has been used on 25 patients of 
the 25 patients treated none had any ulceration or soft tissue damage 
 
 2011 
 
 Steiert A, Hille U, Burke 
W, Gohritz A, Zilz S, 
Herold C, Vogt PM. 
Subcutaneous wash-out 
procedure (SWOP) for the 
treatment of 
chemotherapeutic 
extravasations.  J Plast 
Reconstr Aesthet Surg. 
2011 Feb;64(2):240-7. 
Epub 2010 Jun 9.  
Hypothesis / Abstract 
Report on a therapeutic approach 
using saline washout procedure 
without the application of specific 
antidotes.  Advocates that based on 
the absence of comparative studies 
with regard to the efficacy of 
conservative therapy, SWOP should 
be offered as a therapeutic option 
for chemotherapeutic 
extravasations.                                      
Design                     
Prospective case series 
Intervention                     
SALINE WASHOUT 
13 patients 
 
OCEBM – Level    4 
 
 
 
 
 P- 13 patients 
I- Saline washout 
C- historical control of surgery 
O- none of the patients required surgery 
R-no randomisation or control arm – all extravasations included 
Multiple different drugs 
A- varying volumes of saline used dependant on volume of extravasate, All 
accounted for 
M- objective measures as in not requiring washout, but subjective in 
measurement of skin induration or other sequalae 
Outcome = positive 
Includes CVAD extravasations Cites Gault 1993 but has changed the 
procedure slightly Backs up MVCC rationale for treating category 1-3 
extravasations with SWOP Say it can potentially be used 72hrs post 
extravasation 
13 patients, 3 month follow up, Focused on outcome 
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Date  Reference Hypothesis / aim of study Study design  / intervention Sample size and level 
of evidence  
(OCEBM 2011)  
Main Findings 
(Appraised using PICO or CASP dependant on study design) 
 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gopalakrishnan PN, Goel 
N, Banerjee S. Saline 
irrigation for the 
management of skin 
extravasation injury in 
neonates. 
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Issue 2. Art. No.: 
CD008404. DOI: 
10.1002/14651858.CD008
404.pub2 
Copyright © 2012 The 
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Aim: To determine the efficacy and 
safety of saline irrigation or saline 
irrigation with prior hyaluronidase 
infiltration on tissue healing in 
neonates with extravasation injury 
when compared to no intervention 
or normal wound care. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Design 
Systematic review of the 
literature 
Cochrane review 
 
Intervention 
SALINE IRRIGATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OCEBM –Level 1  
Cochrane review 
 
Clearly defined research question 
 Clearly defined search strategy                                 
SELECTION CRITERIA: Randomised controlled trials (RCT) and quasi-
randomised controlled trials comparing saline irrigation with or without 
hyaluronidase infiltration with no intervention or normal wound care in the 
management of extravasation injury in neonates.   
DATA COLLECTION AND ANALYSIS: three review authors 
independently reviewed and identified articles for possible inclusion in this 
review.           
MAIN RESULTS: No eligible studies were found. There were a few case 
reports and case series describing successful outcomes with different 
interventions in this condition.                                    
Authors' Conclusions: To date, no randomised controlled trial is available 
that examines the effects of saline irrigation with or without prior 
hyaluronidase infiltration in the management of extravasation injury in 
neonates. Saline irrigation is a frequently reported intervention in the 
literature that is used in the management of extravasation injury in neonates. 
Research should be initially directed at evaluating the efficacy and safety of 
this intervention through randomised controlled trials. It will also be 
important to determine the size of the effect according to timing of 
intervention, nature of the infusate and the severity of injury at the time of 
intervention. 
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